Fmoc-N-Methyl-tranexamic acid is a chemically modified derivative of tranexamic acid, a well-known antifibrinolytic agent. The molecule features a tranexamic acid backbone with an N-methyl group and an N-terminal 9-fluorenylmethoxycarbonyl (Fmoc) protecting group. This specific modification is designed for use in solid-phase peptide synthesis (SPPS). Its primary application is as a specialized, protected amino acid building block in peptide chemistry. The Fmoc group is a standard protecting group for amines in Fmoc-based SPPS, allowing for orthogonal deprotection under mild basic conditions. The incorporation of the N-methylated tranexamic acid moiety into peptide sequences is a strategy to enhance metabolic stability, alter conformational properties, and potentially improve the pharmacokinetic profile of the resulting therapeutic peptides. It is therefore a key reagent in the research and development of novel peptide-based pharmaceuticals, particularly those targeting conditions related to fibrinolysis or requiring protease resistance. The compound is a high-purity synthetic intermediate, typically supplied for research purposes. Handling requires standard precautions for laboratory chemicals, and it should be stored under inert conditions to preserve the integrity of the Fmoc group.